RNAZ Earnings

Quarterly EPS
$-146.06
Q3 2024
$-133.73
Q4 2024
$-70.16
Q1 2025
$-5.13
Q2 2025
$-5.82
Q3 2025
$-16.38
Q4 2025
$-21.28
Q1 2026
$-7.17
Q2 2026
Latest RevenueN/A
Latest Net Income-6750128
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$7.170-6750128-39.8%
Q1 2026-$21.280-17785071+69.7%
Q4 2025-$16.380-13443110+87.8%
Q3 2025-$5.820-4856051+96.0%
Q2 2025-$5.130-4276502+99.2%
Q1 2025-$70.160-12085413+88.3%
Q4 2024-$133.730-5915958+34.9%
Q3 2024-$146.060-2321387+99.7%
Q2 2024-$680.230-5190814
Q1 2024-$597.800-3326812
Q4 2023-$205.290-4087547
Q3 2023-$44,758.560-5299962
TransCode Therapeutics (RNAZ) — Earnings